AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 222 min read$TARS

Azamian Bobak R. sold $615K of TARS (indirect holdings)

Azamian Bobak R. (President/CEO and Board Chair) sold 10,000 indirectly-held shares of Tarsus Pharmaceuticals, Inc. (TARS) at an average of $61.55 ($61.24–$61.81, $0.62M total) across 2 trades on 2026-06-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Azamian Bobak R.
Published Jun 22, 2026, 8:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 22, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TARS
Neutral
medium confidence
Mentioned
$TARS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TARSNeutralLow
01

Why it matters

The newest fact is the CEO/Chair’s open-market sale amount, timing, and confirmation that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

This provides a fresh, timestamped insider-selling datapoint, but it does not include any new business or financial guidance information.

03

What to watch

Traders may over-weight insider sales; without changes in guidance/clinical milestones, the filing is mostly a sentiment datapoint.

Relevance 4/10Novelty 5/10Timing: after-hours/filing update (filed 2026-06-22)

Background

The article is an SEC Form 4 insider transaction disclosure for Tarsus Pharmaceuticals, Inc.

Company-level read

Ticker impact

$TARSNeutralMedium confidence
Context

SEC Form 4 shows Tarsus Pharmaceuticals CEO/Chair Azamian Bobak R. sold $615,488 of TARS shares via a 10b5-1 plan on 2026-06-17.

Expected impact

Likely limited near-term impact; any effect should fade unless follow-on selling accelerates.

Evidence & confidence

The filing is a pre-arranged 10b5-1 open-market sale by the CEO/Chair, with no accompanying operational or guidance news in the text.

Market effects

Sector

Minimal; this is company-specific insider trading with no sector-wide regulatory/clinical catalyst mentioned.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because it’s a 10b5-1 plan, the sale may be mechanically scheduled and not predictive of near-term downside.

Key entities

  • issuer
    Tarsus Pharmaceuticals, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Azamian Bobak R.

    President/CEO and Board Chair who sold shares under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TARS insider trading history →

Related articles

SEP 16
$TARSMed

TARS Reinstated by Barclays -- Rating Upgraded to Overweight

Barclays reinstated Tarsus Pharmaceuticals (TARS) with an Overweight rating and a $110.00 price target. The company's stock is currently trading at $78.23, with a GF Value™ of $160.86, indicating a 51.4% undervaluation. TARS has a GF Score™ of 46/100, reflecting mixed financial health and performance. The company focuses on biotechnology, particularly eye care, with its lead product being XDEMVY.

gurufocus.com2 min
SEP 10
$TARSHighAI 8/10

Tarsus Pharmaceuticals, Inc. (TARS): Completion of Acquisition or Disposition of Assets

Tarsus Pharmaceuticals, Inc. (TARS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care September 4, 2026 Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt’s disease, a pote

SEC EDGAR 8-K2 min
SEP 8
$TARSMed

Jefferies raises Tarsus Pharmaceuticals price target on guidance

Jefferies raised its price target on Tarsus Pharmaceuticals (NASDAQ:TARS) to $105, citing strong guidance and recent prescription data. The stock has surged 23% in the past week. Tarsus reported Q2 2026 sales of $173.9M, beating expectations, and raised full-year sales guidance for XDEMVY. The company has a market cap of approximately $4B and is considered undervalued by InvestingPro analysis.

investing.com2 min
SEP 4
$TARSMed

Tarsus Pharmaceuticals Completes Alkeus Acquisition; Adds Phase 3 Stargardt Disease Program

Tarsus Pharmaceuticals (TARS) completed its acquisition of Alkeus Pharmaceuticals, gaining worldwide rights to ALK-001, a Phase 3 investigational therapy for Stargardt disease. ALK-001 has received multiple FDA designations and is expected to report topline data in 2029. The acquisition expands Tarsus' pipeline and supports its eye care strategy. TARS shares closed at $83.21 on Thursday, up 0.54%.

rttnews.com2 min
SEP 4
$TARSMed

A potentially blinding eye disease has no FDA-approved therapy. Tarsus bought a company developing one.

Tarsus Pharmaceuticals (TARS) completed its acquisition of Alkeus Pharmaceuticals, gaining worldwide rights to ALK-001, a late-stage oral therapy for Stargardt disease. ALK-001 has received multiple FDA designations and is in a Phase 3 trial with topline data expected in 2029. Tarsus believes ALK-001 could be a blockbuster treatment for this inherited retinal disease with no FDA-approved therapies.

stocktitan.net2 min